- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05992545
Mobile Application for Integrative Diabetes Care
August 15, 2023 updated by: Bae, Jae Hyun, Korea University Anam Hospital
Diabetes Care Via a Mobile Application on Integrating Physical and Mental Health: A Pilot Study
The investigators have developed a mobile application named 'DangDang Care' (which conveys the meaning of managing diabetes confidently and consistently through psychological care) designed to provide psychological support and enhance diabetes self-management for people with type 2 diabetes experiencing depressive symptoms.
The application incorporates a behavioral activation program.
Subsequently, the investigators conducted a 12-week randomized controlled trial, enrolling individuals with type 2 diabetes and mild-to-moderate depression, with the assistance of public health centers.
The trial aimed to assess the effectiveness and feasibility of the application in promoting consistent diabetes management through added psychological care.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
73
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 02841
- Korea University Anam Hospital
-
Seoul, Korea, Republic of
- Korea University Anam Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Adults aged 20 to 80 years with type 2 diabetes
- Individuals belonging to disadvantaged populations, such as medical aid beneficiaries or those classified as low-income groups
- Mild-to-moderate depressive symptoms, defined as a Patient Health Questionnaire-9 (PHQ-9) score between 5 and 19
- Capable of reading and understanding Korean and using a mobile application
- Having a clear understanding of the study's purpose and providing written consent
Exclusion Criteria:
- Type 1 diabetes or gestational diabetes
- Diabetes complications that hindered diabetes self-management
- Severe depressive symptoms that made app usage and completion of the self-report questionnaire difficult
- Serious mental illnesses other than depressive symptoms (e.g., schizophrenia and related disorders, bipolar and related disorders, or neurodegenerative disorders)
- Serious life-threatening medical conditions
- Physical conditions that impeded mobility
- A history of traumatic brain injury
- Unwillingness to complete the questionnaire and provide personal information
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Mobile application 'DangDang Care' under usual care
The intervention group receives 'DangDang Care' alongside usual diabetes care.
|
The application incorporates a behavioral activation program to provide psychological support and enhance diabetes self-management for people with type 2 diabetes experiencing depressive symptoms, alongside conventional medical therapy. The intervention group receives the mobile application with usual care.
Other Names:
|
|
No Intervention: Usual care
The control group receives only usual diabetes care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in Patient Health Questionnaire-9 (PHQ-9) scores
Time Frame: By week 12
|
The PHQ-9 is a 9-item self-report scale developed to assess the presence and severity of depression within the past 2 weeks.
It was adapted for use with Korean participants.
Respondents rate how often they have been bothered by each problem on a 4-point Likert scale ranging from 0 to 3. The total score ranges from 0 to 27, with higher scores indicating more severe depressive symptoms, and a cutoff score of 10 is used.
|
By week 12
|
|
Changes in Generalized Anxiety Disorder-7 (GAD-7) scores
Time Frame: By week 12
|
The GAD-7 is a brief self-report scale that assesses generalized anxiety disorder, comprising 7 items.
Respondents rate the frequency of experiencing symptoms related to generalized anxiety disorder over the past 2 weeks using a 4-point Likert scale ranging from 0 to 3. Total scores range from 0 to 21, with higher scores indicating more severe anxiety.
In this study, we used the Korean version of the GAD-7, accessible on the Patient Health Questionnaire website.
|
By week 12
|
|
Changes in Korean version of the Perceived Stress Scale (K-PSS) scores
Time Frame: By week 12
|
The Perceived Stress Scale (PSS), originally developed in 1983, was translated into Korean in 2010 and 2012.
The K-PSS consists of 10 items, and respondents rate their responses on a 5-point Likert scale ranging from 0 to 4. The total score ranges from 0 to 40, with higher scores indicating higher perceived stress levels.
|
By week 12
|
|
Changes in Brief Diabetes Distress Screening Instrument (DDS-2) scores
Time Frame: By week 12
|
The DDS-2 is a brief version of the Diabetes Distress Scale, developed in 2008, and was translated into Korean in 2020.
It consists of 2 items, and each item assesses the emotional burden of diabetes and the stress of diabetes management and treatment on a 6-point Likert scale ranging from 1 to 6.
The total score ranges from 2 to 12, with higher scores indicating higher levels of diabetes-related stress.
|
By week 12
|
|
Changes in European Quality of Life-5 Dimensions 3 Level (EQ-5D-3L) index
Time Frame: By week 12
|
The EQ-5D-3L is a tool developed by the Euro Quality of Life Group to assess health-related quality of life.
It comprises a descriptive system with five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Respondents rate their current health state within each domain using three levels.
The evaluative system included the EQ-5D-3L index.
We employed the EQ-5D-3L index to calculate utility values for health states and evaluate the overall quality of life.
|
By week 12
|
|
Changes in Diabetes Self-Efficacy Scale (DSES) scores
Time Frame: By week 12
|
The DSES, originally developed by the Stanford Patient Education Research Center in 2009, was used in its Korean version translated by Young Sun Yeom in her thesis in 2010.
It comprises 8 items, and respondents rate their level of confidence in successfully performing self-care behaviors on a 10-point Likert scale ranging from 1 to 10. Higher scores indicate a higher level of self-efficacy in managing diabetes.
|
By week 12
|
|
Changes in Diabetes Care Profile-Social Support Scale (DCP-SSS) scores
Time Frame: By week 12
|
The Diabetes Care Profile (DCP), developed in 1996, measures psychosocial factors and diabetes treatment.
For this study, only the instrumental and emotional support subscales were utilized, and they were translated into Korean in 2007.
The scale was modified to fit the study's purpose, resulting in a total of 9 items, excluding 3 items not relevant to the study.
Each item was answered on a 5-point Likert scale from 1 to 5, with higher scores indicating higher perceived social support.
|
By week 12
|
|
Changes in Diabetes Self-Management Behaviors for Older Koreans (DSMB-O) scores
Time Frame: By week 12
|
The DSMB-O was developed in 2016 and is based on the self-management standards proposed by the American Association of Diabetes Educators, considering the characteristics of older adults with type 2 diabetes in Korea.
The scale consists of a total of 14 questions, with 9 questions answered on a 4-point Likert scale from 0 to 3, and 5 dichotomous questions.
The total score ranges from 0 to 30, with higher scores indicating higher levels of diabetes self-care behaviors.
|
By week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in glycated hemoglobin (%)
Time Frame: By week 12
|
Measures average blood glucose levels over the past 2-3 months through venous blood sampling.
|
By week 12
|
|
Changes in fasting plasma glucose levels (mg/dL)
Time Frame: By week 12
|
Measures glucose levels after an 8-hour fasting period through venous blood sampling.
|
By week 12
|
|
Change in lipid profiles, including total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol (mg/dL)
Time Frame: By week 12
|
Measures total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) after an 8-hour fasting period through venous blood sampling.
|
By week 12
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Persistent changes in Patient Health Questionnaire-9 (PHQ-9) scores
Time Frame: By week 16
|
The PHQ-9 is a 9-item self-report scale developed to assess the presence and severity of depression within the past 2 weeks.
It was adapted for use with Korean participants.
Respondents rate how often they have been bothered by each problem on a 4-point Likert scale ranging from 0 to 3. The total score ranges from 0 to 27, with higher scores indicating more severe depressive symptoms, and a cutoff score of 10 is used.
|
By week 16
|
|
Persistent changes in Generalized Anxiety Disorder-7 (GAD-7) scores
Time Frame: By week 16
|
The GAD-7 is a brief self-report scale that assesses generalized anxiety disorder, comprising 7 items.
Respondents rate the frequency of experiencing symptoms related to generalized anxiety disorder over the past 2 weeks using a 4-point Likert scale ranging from 0 to 3. Total scores range from 0 to 21, with higher scores indicating more severe anxiety.
In this study, we used the Korean version of the GAD-7, accessible on the Patient Health Questionnaire website.
|
By week 16
|
|
Persistent changes in Korean version of the Perceived Stress Scale (K-PSS) scores
Time Frame: By week 16
|
The Perceived Stress Scale (PSS), originally developed in 1983, was translated into Korean in 2010 and 2012.
The K-PSS consists of 10 items, and respondents rate their responses on a 5-point Likert scale ranging from 0 to 4. The total score ranges from 0 to 40, with higher scores indicating higher perceived stress levels.
|
By week 16
|
|
Persistent changes in Brief Diabetes Distress Screening Instrument (DDS-2) scores
Time Frame: By week 16
|
The DDS-2 is a brief version of the Diabetes Distress Scale, developed in 2008, and was translated into Korean in 2020.
It consists of 2 items, and each item assesses the emotional burden of diabetes and the stress of diabetes management and treatment on a 6-point Likert scale ranging from 1 to 6.
The total score ranges from 2 to 12, with higher scores indicating higher levels of diabetes-related stress.
|
By week 16
|
|
Persistent changes in European Quality of Life-5 Dimensions 3 Level (EQ-5D-3L) index
Time Frame: By week 16
|
The EQ-5D-3L is a tool developed by the Euro Quality of Life Group to assess health-related quality of life.
It comprises a descriptive system with five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Respondents rate their current health state within each domain using three levels.
The evaluative system included the EQ-5D-3L index.
We employed the EQ-5D-3L index to calculate utility values for health states and evaluate the overall quality of life.
|
By week 16
|
|
Persistent changes in Diabetes Self-Efficacy Scale (DSES) scores
Time Frame: By week 16
|
The DSES, originally developed by the Stanford Patient Education Research Center in 2009, was used in its Korean version translated by Young Sun Yeom in her thesis in 2010.
It comprises 8 items, and respondents rate their level of confidence in successfully performing self-care behaviors on a 10-point Likert scale ranging from 1 to 10. Higher scores indicate a higher level of self-efficacy in managing diabetes.
|
By week 16
|
|
Persisent changes in Diabetes Care Profile-Social Support Scale (DCP-SSS) scores
Time Frame: By week 16
|
The Diabetes Care Profile (DCP), developed in 1996, measures psychosocial factors and diabetes treatment.
For this study, only the instrumental and emotional support subscales were utilized, and they were translated into Korean in 2007.
The scale was modified to fit the study's purpose, resulting in a total of 9 items, excluding 3 items not relevant to the study.
Each item was answered on a 5-point Likert scale from 1 to 5, with higher scores indicating higher perceived social support.
|
By week 16
|
|
Persistent changes in Diabetes Self-Management Behaviors for Older Koreans (DSMB-O) scores
Time Frame: By week 16
|
The DSMB-O was developed in 2016 and is based on the self-management standards proposed by the American Association of Diabetes Educators, considering the characteristics of older adults with type 2 diabetes in Korea.
The scale consists of a total of 14 questions, with 9 questions answered on a 4-point Likert scale from 0 to 3, and 5 dichotomous questions.
The total score ranges from 0 to 30, with higher scores indicating higher levels of diabetes self-care behaviors.
|
By week 16
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 13, 2022
Primary Completion (Actual)
January 13, 2023
Study Completion (Actual)
July 21, 2023
Study Registration Dates
First Submitted
July 23, 2023
First Submitted That Met QC Criteria
August 7, 2023
First Posted (Actual)
August 15, 2023
Study Record Updates
Last Update Posted (Actual)
August 18, 2023
Last Update Submitted That Met QC Criteria
August 15, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DangDangCare
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
Massachusetts General HospitalRecruitingDepression | Depression - Major Depressive Disorder | Depression Chronic | Depression in Adults | Depression Disorders | Depression DisorderUnited States
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)Active, not recruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
ProgenaBiomeWithdrawnDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Sorlandet Hospital HFUniversity of Oslo; Karolinska Institutet; Australian Catholic University; Helse...RecruitingAnxiety | Anxiety Depression | Depression Anxiety Disorder | Depression - Major Depressive DisorderNorway
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Lipocine Inc.CompletedDepression, Postpartum | Postnatal Depression | Peripartum Depression | Depression, Post-Partum | Postpartum Depression (PPD) | Post-Natal DepressionUnited States
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Kolby Walker, DO; Brittany KimbleRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryActive, not recruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of MinnesotaCompletedDepression SymptomsUnited States
-
University of CincinnatiNational Center for Complementary and Integrative Health (NCCIH)RecruitingMild DepressionUnited States
Clinical Trials on Mobile application 'DangDang Care' under usual care
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedQuality of Life | Non Small Cell Lung Cancer | Coping SkillsUnited States
-
Fenerbahce UniversityNot yet recruitingQuality of Life | Symptom Management
-
Akdeniz UniversityCompletedAdolescent | Asthma in Children | Self Efficacy | Nursing CareTurkey
-
University of South CarolinaRecruiting
-
Universiti Teknologi MaraRecruiting
-
The University of Texas Health Science Center,...Completed
-
Indiana UniversityNational Cancer Institute (NCI)WithdrawnPediatric Cancer
-
Diakonhjemmet HospitalThe Dam Foundation; The Norwegian Council for Musculoskeletal HealthActive, not recruiting
-
Massachusetts General HospitalThe Leukemia and Lymphoma SocietyActive, not recruitingHematologic Malignancy | Bone Marrow Transplant ComplicationsUnited States
-
University of ReginaCompletedStress | Dementia | Caregiver BurdenCanada